NVAX • NASDAQ
Novavax, Inc.
$57.15
After Hours:
$56.98
(0.30%)-0.17
Closed: Jul 1, 7:59:37 PM GMT-4 · USD · NASDAQ · Disclaimer
Top gainerStockUS listed securityUS headquartered
Previous close
$51.43
Day range
$50.88 - $57.56
Year range
$34.88 - $277.80
Market cap
4.47B USD
Avg Volume
7.00M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Financial performance
Revenue
Net income
(USD)Mar 2022Y/Y change
Revenue
703.97M57.41%
Operating expense
95.99M51.91%
Net income
203.41M191.33%
Earnings per share
2.56183.93%
EBITDA
216.06M204.72%
Effective tax rate
1.29%
Financial performance
Total assets
Total liabilities
(USD)Mar 2022Y/Y change
Cash and short-term investments
1.57B-21.36%
Total assets
2.83B8.68%
Total liabilities
2.77B76.49%
Total equity
65.32M
Shares outstanding
78.13M
Price to book
61.23
Return on assets
19.34%
Return on capital
134.80%
Financial performance
Net change in cash
(USD)Mar 2022Y/Y change
Net income
203.41M191.33%
Cash from operations
-88.51M-113.35%
Cash from investing
-16.83M-111.88%
Cash from financing
159.86M-72.29%
Net change in cash
55.84M-95.95%
Free cash flow
-425.38M-152.43%
About
Novavax, Inc. is an American biotechnology company based in Gaithersburg, Maryland, that develops vaccines to counter serious infectious diseases. Prior to 2020, company scientists developed experimental vaccines for Ebola, influenza, respiratory syncytial virus, and other emerging infectious diseases. During 2020, the company redirected its efforts to focus on development and approval of its NVX-CoV2373 vaccine for COVID-19. Novavax has indicated it recognizes a continued need for innovative vaccines in other therapeutic areas and reports it has taken steps to ensure continued advancement of its influenza vaccine. Their vaccine, Nuvaxovid, was approved in the European Union at the end of 2021 and in Canada in February 2022, as the fifth vaccine against COVID-19, following Pfizer/BioNTech, Moderna, Janssen and AstraZeneca. Wikipedia
Founded
1987
Employees
1,541
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for